Skip to main content
  • Some antibodies can broadly neutralize ebolaviruses ; Study

    Some survivors of ebolavirus outbreaks make antibodies that can broadly neutralize these viruses--and now, scientists at Scripps Research have illuminated how these antibodies can disable the viruses so effectively. The insights may be helpful for developing effective therapies.

  • Two-vaccine Ebola regimen shows promise in early-stage clinical trial

    Pharma courses

    pharma courses


    An immunization regimen using two Ebola vaccine candidates was safe and well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial. Results from the study are described in the April 19th issue of the Journal of the American Medical Association. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has supported the development and testing of the two investigational vaccines: Ad26.ZEBOV, developed by Crucell Holland B.V., and MVA-BN-Filo, developed by Bavarian Nordic.

  • New form of Ebola virus may cause disease in humans

    Pharma courses

    pharma courses


    The Reston virus, a member of the Ebola virus family which is known to circulate in domestic pigs in Asia, may acquire the few mutations necessary to cause disease in humans and to develop into a novel health threat, researchers have warned.

  • Single antibody from human survivor show promise against Ebola

    Pharma courses

    pharma courses


    In an important advancement towards an effective treatment against the deadly Ebola virus disease (EVD), researchers have found that a single monoclonal antibody isolated from a human survivor completely protects monkeys from lethal infection with the virus.

  • Human antibodies from survivors to kill Ebola viruses

    Pharma courses

    pharma courses


    In what could be termed as “silver bullet” for Ebola viruses, a team of researchers has isolated human antibodies from Ebola survivors which can neutralise multiple species of the virus that has killed more than 11,000 people in West Africa in the past two years.

  • Guinea declared Ebola-free

    Pharma courses

    pharma courses


    The World Health Organisation on Tuesday declared the end of the Ebola outbreak in the West African nation of Guinea, two years after the beginning of the epidemic.

  • Merck’s investigational Ebola vaccine for Emergency Use Assessment and Listing accepted for review by WHO

    Pharma courses

    pharma courses


    Merck, known as MSD outside the United States and Canada, announced that the application for Emergency Use Assessment and Listing (EUAL) for the company’s investigational Ebola Zaire vaccine, V920 (rVSV?G-ZEBOV-GP, live attenuated), has been accepted for review by the World Health Organization (WHO).

Subscribe to Ebola

Search this website